Skip Navigation


European Heart Journal Advance Access originally published online on December 7, 2005
European Heart Journal 2006 27(3):251-252; doi:10.1093/eurheartj/ehi678
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/3/251    most recent
ehi678v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Khan, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Khan, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

How many patients need cardiac resynchronization therapy?

John G.F. Cleland*, Kevin Goode, Olga Khaleva and Nasrin Khan

Department of Cardiology, Castle Hill Hospital, University of Hull, Kingston upon Hull, UK

* Corresponding author. Tel: +44 1482 624 087; fax: +44 1482 624 085. E-mail address: j.g.cleland@hull.ac.uk

This editorial refers to ‘How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts’{dagger} by F.A. McAlister et al., on page 323

The first 10% of the full text of this article appears below.

For patients with moderate or severe heart failure who have evidence of cardiac dyssynchrony there is overwhelming evidence that cardiac resynchronization therapy (CRT) improves symptoms substantially, reduces morbidity, and prolongs life.1 The CARE-HF programme demonstrated that CRT reduced all-cause mortality by 40% and cardiovascular mortality by about 45%.2 The COMPANION trial, which was stopped prematurely, and a meta-analysis of CRT trials including 3393 patients, are consistent with these data.1 In CARE-HF, the absolute reduction in mortality was 13.4%,2 which translates into a life saved for every 7.5 devices implanted over an average 3-year follow-up. The treatment appears cost-effective. In summary, there is no doubt that CRT is valuable in patients similar to those recruited in the clinical trials. Resources now have to be found to implement their results.

Effective planning requires some idea . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts
Finlay A. McAlister, Jack V. Tu, Alice Newman, Douglas S. Lee, Shane Kimber, Bibiana Cujec, and Paul W. Armstrong
EHJ 2006 27: 323-329. [Abstract] [FREE Full Text]